Navigation Links
Publication on 'Tregitopes' in Blood Journal of October 2008

PROVIDENCE, R.I., Oct. 27 /PRNewswire/ -- Dr. Annie De Groot, CEO of EpiVax, is the lead author on an article highlighting key findings about the activation of natural regulatory T cells by IgG Fc-derived peptide, also known as Epi-13 or "Tregitopes." These findings were published in the October 8 issue of the prestigious Blood, the medical journal published by the American Society of Hematology.

In an accompanying editorial, Rachel Caspi of the National Institutes of Health (NIH) wrote, "This important finding has the potential to explain tolerance to human antibody variable regions, the effects of immunoglobulin-Ag conjugates, the weak immunogenicity of Fc fusion proteins, and the therapeutic and regulatory effects of clinical preparations of IVIg on autoimmune and inflammatory diseases." De Groot is the principal investigator of newly awarded grants from the NIH and the Montel Williams Foundation to explore the use of the Tregitopes in Type 1 Diabetes (Juvenile Diabetes) and Multiple Sclerosis, respectively.

About Autoimmune Diseases

In most patients with autoimmune disease, responses to the body's own proteins cause tissue damage or dysregulation of normal body functions. Autoimmune diseases include such illnesses as Rheumatoid Arthritis, Juvenile Diabetes, Multiple Sclerosis, and others The approach used by EpiVax is called "Antigen-Specific Adaptive Tolerance Induction (ASATI(TM))" to specifically target and reduce undesirable immune responses. EpiVax used its proprietary computer algorithms to identify the molecules that induce ASATI.

Because ASATI uses the body's own natural responses, this intervention has the potential to be far safer than immunosuppressive drugs that are now being studied. The promising treatment, called Epi-13(TM), may have application to a broad range of auto-immune disorders.

About Epi-13(TM)

Epi-13(TM) is a group of "Tregitope" peptides that induce the body's own natural regulatory T cells. When administered in conjunction with other antigens or protein immunogens, the response to these immunogens is diminished and altered if the antigen/immunogens are co-administered with Epi-13. Preliminary in vitro and in vivo studies indicate that the modification of the immune response is due to the induction of natural T reg cells.

About EpiVax

EpiVax, Inc. is a biotechnology company that is dedicated to merging in vitro immunology research with bioinformatics to generate new therapeutics for cancer and autoimmune diseases as well as new vaccines for infectious diseases such as HIV, TB, and hepatitis. T cell epitope mapping, the selection of target peptides from any protein sequence, is a powerful resource for the development of novel protein therapeutics. EpiVax research shows that peptides chosen by EpiMatrix(TM) software are highly likely to provoke an immune response when presented to T cells. EpiVax tools can also accurately deimmunize proteins. For more information about EpiVax, please visit

SOURCE EpiVax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
2. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
3. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
4. Ondine Announces Publication of Positive Results from Pseudomonas aeruginosa Eradication Study
5. Resverlogixs Lead Drug Featured in Key Scientific Publication
6. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
7. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
8. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
9. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
10. Industry Executives Finding Value in Shift of Scientific Publications
11. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Post Your Comments:
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):